Clinical trials in acute severe asthma: are type II errors important?

M J WARD

From the Departments of Tuberculosis and Chest Diseases and Clinical Pharmacology, Llandough Hospital, Penarth, Glamorgan

ABSTRACT Many studies in acute severe asthma have had low power. Fifteen randomised double blind studies investigating the treatment of acute severe asthma published during 1974–84 were analysed for power and 95% confidence limits. Twelve studies failed to detect a significant difference in bronchodilatation produced by two treatments and reported the treatments to produce equal effect. Each study had, however, less than a 60% probability of detecting a true 25% difference in bronchodilatation.

The surprisingly few double blind studies comparing treatments in acute severe asthma have reported disparate results. The treatments studied have included corticosteroids, sympathomimetics, and aminophylline. The place of corticosteroid treatment is unclear. Many studies have claimed that no benefit follows but Macdonald and others have recommended the use of corticosteroids. While there is no doubt that sympathomimetic drugs are life saving in severe asthma there is argument about the best route of administration. Theoretically sympathomimetics such as salbutamol might be expected to produce better bronchodilatation when given parenterally than by inhalation, but reports suggest that this is not the case. Investigators have also made varying claims about aminophylline, some reporting it to be extremely useful, others preferring not to use it.

How may these differing statements be explained, and how should we investigate the treatment of severe asthma in the future? Trials so far have concentrated on tests of statistical significance. Although the familiar expression \( p < 0.05 \) means that the observed difference between treatments could arise by chance in less than one in 20 trials (type I error), a non-significant difference between treatments does not mean that the treatments produce the same result. Whether trials reporting no difference between treatment regimens were ever likely to demonstrate a difference (their power) depends on their design and the number of patients studied. A recent review of 71 studies with negative results showed that because of low power most had a considerable chance of not being able to detect a clinically useful difference between treatments (type II error).

Many workers have compared two treatments in severe asthma and on finding “no significant” difference \( (p > 0.05) \) between the results of treatment have concluded that the treatments produce equal effect. To assess the outcome of reported trials in severe asthma I have analysed double blind randomised studies comparing one treatment with another in terms of the statistical significance of any differences observed, 95% confidence limits for the results of treatment, and the power of the study to detect a real difference between treatments.

Methods

Twenty two trials investigating the use of corticosteroid drugs or intravenous bronchodilators in the treatment of acute severe asthma published during 1974–84 were identified through Index Medicus. Fifteen were randomised, controlled, and double blind and the results of these have been analysed. In each study the bronchodilator response, measured by increase (mean and standard deviation) in peak expiratory flow rate (PEF) or FEV\(_1\), was noted along with the study size and level of significance recorded in the paper. One study reported PEF and FEV\(_1\) and both were analysed.

If a trial reports no significant difference between treatments \( (p > 0.05) \) then it is necessary to ask whether the trial would have been able to detect a difference, and what degree of difference would be clinically relevant. The percentage increase in bron-
Clinical trials in acute severe asthma: are type II errors important?

Cholinolatation produced by each treatment was calculated and the difference noted. The power of the studies to detect differences in bronchodilator response of 25% and 50% was calculated (fig 1); both of these values were decided arbitrarily as being levels that would have practical relevance. In all cases "percentage difference in bronchodilatation" refers to the percentage increase from baseline produced by one treatment minus the percentage increase from baseline produced by another.

An operating characteristic curve was drawn for each study, based on the description of Freiman.7 The value of β (the probability of making a false negative or type II error) was calculated on the assumption that the level of statistical significance with a two tailed test was α = 0.05. A typical curve is shown in figure 1. In this case the total number of patients studied was 14. The mean PEF rose with intravenous salbutamol from 86 to 124 l min⁻¹—that is, by 38 l min⁻¹ (an increase of 44%). The SD of changes between subjects was 60 l min⁻¹. Nebulised salbutamol produced an increase from 82 to 133 l min⁻¹ that is, 51 l min⁻¹ (62%), SD = 50. The difference between treatments was not significant and it was concluded that the treatments produced equal effect.

On the basis of the nomogram described by Altman,8 SD and N are used to calculate the probability (1-β) of detecting differences (D) between treatments of 10 to 100 l min⁻¹. In the curve values of

![Beta curve](image)

Fig 1 Operating characteristic of a representative trial.

D are related to the vertical scale of β—that is, the probability of making a false negative error.

Percentage difference between treatments was calculated as follows. Nebulised treatment produced a 44% increase in PEF and for intravenous treatment

<table>
<thead>
<tr>
<th>Description of trial</th>
<th>Value of 1-β for 25% difference between treatments</th>
<th>Value of 1-β for 50% difference between treatments</th>
<th>Actual difference reported (%)</th>
<th>No of patients studied and assessment (PEF or FEV₁)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrocortisone/placebo⁷</td>
<td>0.4</td>
<td>&gt;0.9</td>
<td>5</td>
<td>19 (PEF)</td>
</tr>
<tr>
<td>Corticosteroid/placebo⁸</td>
<td>0.6</td>
<td>&gt;0.9</td>
<td>1</td>
<td>45 (FEV₁)</td>
</tr>
<tr>
<td>Hydrocortisone/placebo¹¹</td>
<td>0.46</td>
<td>&gt;0.9</td>
<td>6</td>
<td>38 (FEV₁)</td>
</tr>
<tr>
<td>Methylprednisolone/high dose/low dose¹²</td>
<td>0.5</td>
<td>&gt;0.9</td>
<td>15</td>
<td>16 (FEV₁)</td>
</tr>
<tr>
<td>Hydrocortisone/placebo¹³</td>
<td>0.3</td>
<td>&gt;0.9</td>
<td>60</td>
<td>20 (FEV₁)</td>
</tr>
<tr>
<td>Salbutamol intravenous/ nebulised¹⁴</td>
<td>0.05</td>
<td>0.3</td>
<td>18</td>
<td>14 (PEF)</td>
</tr>
<tr>
<td></td>
<td>0.15</td>
<td>0.5</td>
<td>5</td>
<td>20 (PEF)</td>
</tr>
<tr>
<td></td>
<td>0.5</td>
<td>&gt;0.9</td>
<td>24</td>
<td>14 (FEV₁)</td>
</tr>
<tr>
<td>Salbutamol/aminophylline⁵</td>
<td>0.3</td>
<td>0.7</td>
<td>27</td>
<td>13 (PEF)</td>
</tr>
<tr>
<td>Salbutamol/aminophylline¹³</td>
<td>0.1</td>
<td>0.3</td>
<td>66</td>
<td>20 (PEF)</td>
</tr>
<tr>
<td>Isoprenaline/aminophylline⁶</td>
<td>0.5</td>
<td>&gt;0.9</td>
<td>41</td>
<td>32 (FEV₁)</td>
</tr>
<tr>
<td>Adrenaline/adrenaline</td>
<td>0.5</td>
<td>&gt;0.9</td>
<td>1</td>
<td>51 (PEF)</td>
</tr>
<tr>
<td>Isoprenaline/isoprenaline + aminophylline¹⁸</td>
<td>0.6</td>
<td>&gt;0.9</td>
<td>9</td>
<td>102 (FEV₁)</td>
</tr>
<tr>
<td>Salbutamol/salbutamol + aminophylline¹⁷</td>
<td>0.4</td>
<td>&gt;0.9</td>
<td>16</td>
<td>39 (PEF)</td>
</tr>
<tr>
<td>Salbutamol/salbutamol + aminophylline⁵</td>
<td>0.35</td>
<td>0.9</td>
<td>40</td>
<td>15 (FEV₁)</td>
</tr>
<tr>
<td>Adrenaline/adrenaline or isoprenaline + aminophylline¹⁹</td>
<td>0.7</td>
<td>&gt;0.9</td>
<td>54</td>
<td>60</td>
</tr>
</tbody>
</table>
to produce 25% more bronchodilatation it would
have to increase the PEF by 69%: an increase of
59 l min\(^{-1}\), which means a difference of 21 l min\(^{-1}\)
from that produced by nebulised treatment alone.

This example shows that the study design used
would result in a 95% (\(\beta = 0.95\)) probability of a
conclusion of no significant difference when the actual
difference was 21 l min\(^{-1}\) (a 25% difference between
treatments) and a 72% probability of showing no
difference when the actual difference was 42 l min\(^{-1}\)
(a 50% difference between treatments).

Ninety five per cent confidence limits were also
determined on the basis of the difference between
mean responses cited, the standard deviation, and the
number of patients studied.

Results

Trials Comparing Corticosteroid with Placebo
There were five studies of the use of corticosteroids in
severe asthma. Four of these were unable to detect a
statistically significant benefit from the treat-
ment.\(^9\)\(^-\)\(^12\) These studies, however, all had less than a
60% (power 0.3-0.6) probability of detecting 25% more
bronchodilatation in those treated with cortico-
steroid. None of the trials would have been likely to
miss a true 50% difference in bronchodilatation
caused by the treatments (table 1). The 95% confidence
limits for the studies are shown in figure 2. The
four negative studies, being unable to detect a
significant benefit from corticosteroid treatment, have
limits crossing the midline zero point. Four of the five
studies, however, reported more bronchodilatation in
those treated with corticosteroid but only one
recorded a statistically significant difference.\(^13\) In this
case the 95% confidence limits lie in favour of steroid
treatment and do not cross the zero line. The power of
this study was, however, no greater than the others,
its significance being related only to the large
difference in response seen.

Comparisons of Intravenous and Nebulised Sympathomimetic Treatment
Two randomised double blind studies have com-
pared nebulised and intravenous salbutamol.\(^6\)\(^-\)\(^14\)
Neither study detected a significant difference
between treatments. Examination of the PEF data in
the studies, however, shows that they had less than a
50% (power 0.3, 0.5) probability of being able to
detect a true 50% difference in increase in PEF pro-
duced by the treatments. One study also reported the
results in terms of FEV\(_1\), and the power of this study
to detect a true 25% difference was 0.5. It had little
probability of missing a 50% difference in broncho-
dilatation (table 1).

![Figure 2](http://example.com/fig2.png)

**Fig 2** Ninety five per cent confidence limits for the five trials
of corticosteroids in acute severe asthma. The vertical bar at
the centre of each interval indicates the reported percentage
difference in treatments. The true difference has a 95% chance of lying somewhere between the outer bars.

The 95% confidence limits are shown in figure 3. Although all cross the midline, the limits are wide and
substantial differences in favour of intravenous treatment
are still possible.

Trials Comparing Aminophylline Alone
with a Sympathomimetic Alone
Three randomised controlled trials have compared

![Figure 3](http://example.com/fig3.png)

**Fig 3** Ninety five per cent confidence limits for the trials of
intravenous and nebulised salbutamol in severe asthma. The
top two bars represent PEF data, and the other refers to
FEV\(_1\). (See note about confidence limits and the vertical bar
in fig 2.)
Clinical trials in acute severe asthma: are type II errors important?

Fig 4 Ninety five per cent confidence limits for the trials concerned with the bronchodilatation produced by intravenous aminophylline and by a sympathomimetic (β agonist) drug. (See note about confidence limits and the vertical bar in fig 2.)

either salbutamol or isoprenaline with aminophylline.\textsuperscript{5,6,15} In two no difference was reported between treatments but both of these had a large type II error, having less than a 30% (power 0·1, 0·3) probability of detecting a true 25% difference in response to the treatments (table 1). The third study reported significantly more bronchodilatation in those treated with inhaled isoprenaline (fig 4).

**COMPARISON OF SYMPATHOMIMETIC DRUGS USED ALONE AND WITH AMINOPHYLLINE**

Five randomised controlled trials have measured bronchodilatation following a sympathomimetic given alone or in combination with aminophylline.\textsuperscript{5,16–19} The sympathomimetic varied in the studies and two used intravenous salbutamol, one inhaled isoprenaline, and two subcutaneous adrenaline.

These trials had less than a 70% (power 0·35–0·7) chance of detecting a 25% difference in bronchodilatation (table 1). All had high probability of being able to detect a 50% difference between treatments. Two studies reported a clear benefit from using aminophylline with salbutamol or adrenaline (fig 5).

**Discussion**

In the treatment of severe asthma it is reasonable to suppose that a difference of 25% in the degree of bronchodilatation produced by two treatments would be clinically useful. Twelve of 15 studies in severe asthma have been unable to detect differences in treatment and it has been concluded that the treatments produce equal effect. The failure to attain a level of statistical significance, however, does not necessarily mean that two treatments being compared are identical. The 12 studies had less than a 60% probability of detecting a true 25% difference in treatments.

There has been much debate concerning the use of corticosteroids in severe asthma and, although the studies reported no benefit from the treatment, it is clear that they had large type II error and may have been unable to detect a clinically useful difference. Although differences were not statistically significant, examination of the 95% confidence limits (fig 2) shows the effect of corticosteroid treatment to be mostly in favour of treatment. This, in addition to the results in favour of corticosteroids in retrospective studies, supports the continued prescription of corticosteroids in severe asthma.

Editorial advice that in severe asthma nebulised salbutamol is as good as intravenous may be incorrect.\textsuperscript{20} There have been few controlled studies on this subject and analysis of published results shows a large type II error, so that clinically useful differences in the effects of treatment might not have been detected.

Analysis of the results of studies comparing intravenous aminophylline alone with a sympathomimetic (β agonist or adrenaline) shows one study with clear 95% confidence limits in favour of salbutamol (fig 4). With regard to studies using aminophylline and sympathomimetics (fig 5), these all report more bronchodilatation with the combination, two studies having 95% confidence limits clear of the zero line. Two of these studies, however, used adrenaline as the sympathomimetic instead of a more powerful selective β agonist like salbutamol. The place of aminophylline remains controversial. There is more evidence in favour of adding aminophylline to a β agonist than using aminophylline alone (figs 4 and 5). Whether a larger dose of either drug used alone would have
Table 2  Details of drugs used in trials comparing treatments in acute severe asthma

<table>
<thead>
<tr>
<th>Drug administered</th>
<th>Route of administration</th>
<th>Duration of treatment (h)</th>
<th>Total dose (for 70 kg person)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrocortisone⁹</td>
<td>IV</td>
<td>12</td>
<td>980 mg</td>
</tr>
<tr>
<td>Hydrocortisone¹⁰</td>
<td>IV</td>
<td>24</td>
<td>980 mg</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>IV</td>
<td>42</td>
<td>42 mg</td>
</tr>
<tr>
<td>Betamethasone</td>
<td>IV</td>
<td>6</td>
<td>250–1000 mg</td>
</tr>
<tr>
<td>Hydrocortisone¹¹</td>
<td>IV</td>
<td>24</td>
<td>60–500 mg</td>
</tr>
<tr>
<td>Methylprednisolone¹²</td>
<td>IV</td>
<td>24</td>
<td>980 mg</td>
</tr>
<tr>
<td>Hydrocortisone¹³</td>
<td>IV</td>
<td>0.75</td>
<td>900 μg</td>
</tr>
<tr>
<td>Salbutamol⁴</td>
<td>Neb</td>
<td>1</td>
<td>10 mg</td>
</tr>
<tr>
<td>Salbutamol¹⁴</td>
<td>Neb</td>
<td>Min of 5 mg/ml sol</td>
<td></td>
</tr>
<tr>
<td>Salbutamol⁵</td>
<td>IV</td>
<td>1</td>
<td>540 μg</td>
</tr>
<tr>
<td>Aminophylline</td>
<td>IV</td>
<td>1</td>
<td>360 mg</td>
</tr>
<tr>
<td>Salbutamol¹³</td>
<td>IV</td>
<td>1</td>
<td>500 μg</td>
</tr>
<tr>
<td>Aminophylline</td>
<td>IV</td>
<td>1</td>
<td>500 mg</td>
</tr>
<tr>
<td>Isoprenaline</td>
<td>Neb</td>
<td>1</td>
<td>7.5 mg</td>
</tr>
<tr>
<td>Aminophylline</td>
<td>IV</td>
<td>1</td>
<td>455 mg</td>
</tr>
<tr>
<td>Adrenaline</td>
<td>SC</td>
<td>1</td>
<td>0.9–1.5 mg</td>
</tr>
<tr>
<td>± aminophylline</td>
<td>IV</td>
<td>1</td>
<td>455 mg</td>
</tr>
<tr>
<td>Isoprenaline</td>
<td>Neb</td>
<td>1</td>
<td>7.5 mg</td>
</tr>
<tr>
<td>± aminophylline</td>
<td>IV</td>
<td>1</td>
<td>455 mg</td>
</tr>
<tr>
<td>Salbutamol</td>
<td>Neb</td>
<td>24</td>
<td>20 mg</td>
</tr>
<tr>
<td>± aminophylline</td>
<td>IV</td>
<td>1</td>
<td>1440 mg</td>
</tr>
<tr>
<td>Salbutamol</td>
<td>IV</td>
<td>1</td>
<td>540 μg</td>
</tr>
<tr>
<td>± aminophylline</td>
<td>IV</td>
<td>1</td>
<td>360 mg</td>
</tr>
<tr>
<td>Adrenaline</td>
<td>SC</td>
<td>1</td>
<td>0.9–1.5 mg</td>
</tr>
<tr>
<td>± aminophylline</td>
<td>IV</td>
<td>1</td>
<td>455 mg</td>
</tr>
</tbody>
</table>

IV—intravenous; Neb—nebuliser; SC—subcutaneous; ±—with and without.

given improved results equalling the effect of the combination is left unanswered by these studies.

Different doses of drug were used in the studies referred to and this makes direct comparisons of results difficult. In most cases, however, the doses used were comparable (table 2).

Future trials comparing treatment regimens in severe asthma need to take the type II error into account and negative studies in particular should include an analysis of the power attained in the study together with 95% confidence limits for the results. It is preferable to plan the requirements of a study in advance. The nomogram published by Altman may be used to calculate the power of a proposed study. An estimate of standard deviation of PEF or FEV₁ for the group to be studied is used to calculate the number of patients required to give a desired probability of detecting a clinically useful difference between treatments. Because patients recover from attacks of severe asthma at very different rates the increase in PEF varies widely from patient to patient and its standard deviation is considerable. For a study to reach a significant result therefore large numbers of patients need to be investigated. The power of a study may be increased by studying a more homogeneous population, such as those known to respond poorly to initial treatment.

I thank Dr Robert Newcombe for his help in the preparation of the manuscript.

References
Clinical trials in acute severe asthma: are type II errors important?

Clinical trials in acute severe asthma: are type II errors important?
M J Ward

Thorax 1986 41: 824-829
doi: 10.1136/thx.41.11.824

Updated information and services can be found at:
http://thorax.bmj.com/content/41/11/824

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/